NCT06610227 is a EARLY_PHASE1 clinical trial of SapRNA™-MICA/B Tumor Vaccine in Advanced Solid Tumors, sponsored by NING LI.

Who is sponsoring NCT06610227?

NCT06610227 is sponsored by NING LI.

What drugs are being tested in NCT06610227?

Interventions in NCT06610227: SapRNA™-MICA/B Tumor Vaccine.

What condition does NCT06610227 study?

NCT06610227 studies Advanced Solid Tumors.

Is NCT06610227 still recruiting?

NCT06610227 is currently active, enrolled. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT06610227

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

Active, enrolled EARLY_PHASE1 Last updated 16 July 2025

What this trial tests

EARLY_PHASE1 trial testing SapRNA™-MICA/B Tumor Vaccine in Advanced Solid Tumors in 18 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 November 2024

Primary endpoint
1 September 2025

1 December 2025

Quick facts

Lead sponsor	NING LI
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	8 November 2024
Primary completion	1 September 2025
Estimated completion	1 December 2025
Sites	1 location across China

Drugs / interventions tested

SapRNA™-MICA/B Tumor Vaccine — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

NING LI — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-arm study to evaluate the safety and efficacy of multiple doses of SapRNA™-MICA/B Tumor Vaccine in patients with advanced solid tumors. Eligible patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively. Follow-up visits will be performed as scheduled after the end of treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Unraveling the potential: mRNA therapeutics in oncology.
Gawalski K, Przybyszewska W, Hunia J, Gawalska A, et al · · 2025 · cited 4× · PMID 40881859 · DOI 10.3389/fonc.2025.1643444
Targeting NKG2D/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications.
Wei H, Xiang L, Zhou Y, Huang Y, et al · · 2026 · cited 1× · PMID 41484787 · DOI 10.1186/s12967-025-07650-5
Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy.
Feng W, Zhao Y, Yu D, Jia W, et al · · 2025 · PMID 41209563 · DOI 10.7150/ijms.120868

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other NING LI trials

Trials by the same sponsor.

NCT06824792 — Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06610227 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NING LI
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06610227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing